Mechanism of Action: Non-Nucleoside Reverse Transcriptase Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Non-Nucleoside Reverse Transcriptase Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | VIRAMUNE | nevirapine | SUSPENSION;ORAL | 020933-001 | Sep 11, 1998 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Mylan | SYMFI LO | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 208255-001 | Feb 5, 2018 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Mylan Labs Ltd | SYMFI | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 022142-001 | Mar 22, 2018 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Msd Merck Co | PIFELTRO | doravirine | TABLET;ORAL | 210806-001 | Aug 30, 2018 | RX | Yes | Yes | 8,486,975 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Msd Merck Co | PIFELTRO | doravirine | TABLET;ORAL | 210806-001 | Aug 30, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Gilead Sciences Inc | ODEFSEY | emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate | TABLET;ORAL | 208351-001 | Mar 1, 2016 | RX | Yes | Yes | 7,125,879 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
